How GlaxoSmithKline Lost Nearly $10B in October Post author:Sam Post published:November 9, 2017 Post category:BioPharma Could GlaxoSmithKline’s industry-leading dividend be at risk? Source: BioSpace You Might Also Like PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment January 10, 2018 2 Tempting Biotech Stocks to Avoid Like Mad March 5, 2017 FDA Calls Cara Therapeutics' Kidney Disease Drug a Breakthrough, Stock Soars June 22, 2017
